



2016 MDF ANNUAL CONFERENCE

September 15-17 2016, Washington DC



MYOTONIC
DYSTROPHY
FOUNDATION

Care and a Cure

FAMILY PLANNING 2016 ANNUAL MYOTONIC DYSTROPHY CONFERENCE SEPTEMBER 17, 2016

Alice Schindler, MS, CGC; Julie Cohen, MS, CGC;
Karin Blackmore, MD

Presentation Overview

- Genetics of DM
 - Alice B. Schindler, MS, CGC
 - NGB/NINDS/NIH
- Pre-conception and prenatal genetic testing
 - Julie Cohen, MS, CGC
 - Kennedy Krieger Institute
- Pregnancy with DM
 - Karin Blackmore, MD
 - Director, Prenatal Genetics, Prenatal Diagnostic Center, Professor of Gynecology and Obstetrics Johns Hopkins School of Medicine



2016 MDF ANNUAL CONFERENCE

September 15-17 2016, Washington DC



MYOTONIC
DYSTROPHY
FOUNDATION


Care and a Cure

GENETICS OF MYOTONIC DYSTROPHY

Myotonic Dystrophy 1 (DM)

- Prevalence 1:20,000 - 3 classifications
 - Mild DM: Onset 20-70 years
 - Cataracts, mild myotonia, diabetes
 - Diagnosis usually after an affected family member
 - Classical DM: Onset 10-30 years
 - Distal muscle weakness, facial weakness, muscle myotonia
ophthalmoplegia, nasal speech, cardiac, cataracts, frontal balding,
endocrinopathies, GI abnormalities, psychological involvement
 - Congenital DM
 - Prenatal – polyhydramnios, reduced fetal movement
 - Neonatal period
 - Hypotonia, generalized weakness, including facial muscles, clubfoot
 - Respiratory insufficiency or failure – mortality - 25% within first 18 months
 - After neonatal period
 - Able to walk but delayed, intellectual disability possible due to early respiratory failure

Chromosome to Gene to Protein



CHROMOSOME

DNA

GENE

PROTEIN

DM1 genetics


- CTG repeats in 3' UTR of DMPK gene located on 19q13
- Autosomal Dominant: mRNA gain of function (abnormal RNA transcript processing)
 - Premutation: 35 to 49
 - Mild: 50 to ~150
 - Classic: ~100 to ~1000
 - Congenital: >2000
- Anticipation typically occurs from maternal allele
 - Maternal CTG repeat <300, risk for child who inherited expanded allele to have congenital DM is 10%. Maternal CTG repeat >300, risk for child who inherited expanded allele to have congenital DM is 59% (Cobo et al. 2002).
- Paternal transmission with anticipation including congenital DM has been reported, but is rare.
- Meiotic and mitotic instable.
- Phase 1: Multiple Doses of ISIS-DMPKRx (antisense drug) in Adults With Myotonic Dystrophy Type 1

DM 2

- **Phenotype:** Similarities to adult-onset DM1: progressive weakness, myotonia, cardiac arrhythmias, cataracts, male hypogonadism, and diabetes.
- Differences from DM1: no congenital form; no intellectual disability in juvenile cases; less weakness in distal, facial, and bulbar; less pronounced muscle atrophy. DM2 patients first seek medical attention for muscle pain, stiffness, fatigue, proximal lower extremity weakness
- **Molecular genetics:** AD, 3q21, ZNF9 (zinc finger protein 9) gene – CCTG repeat expansion in intron 1
 - Normal allele is ≤ 176 bp
 - Borderline allele is between 177-372bp
 - Abnormal allele is >372 bp, but are usually much larger, approx 20,000bp
 - Frequently, repeats can be shorter in offspring after both maternal and paternal transmission

Trinucleotide Repeat Disorders

A **trinucleotide** is a group of 3 chemical bases within a gene. Trinucleotides code for **amino acids**. Amino acids are the building blocks of **proteins**.



TRINUCLEOTIDE C G G

Normal number of repeated trinucleotide segments within a gene = **Normal Protein Function.**





Mildly expanded number of repeated trinucleotide segments = **Normal Protein Function.**



Fully expanded number of repeated trinucleotide segments = **Abnormal or Absent Protein.**





Autosomal Dominant Inheritance



Characteristics of Autosomal Dominant Inheritance

- Multiple generations affected
- Males and females are equally likely to be affected
- Male to male transmission occurs
- Each offspring of an affected parent has a 50% chance of being affected and a 50% chance of being unaffected

Autosomal Dominant Segregation, One Parent Affected




1 in 2 chance (50%) that
the child will be affected

1 in 2 chance (50%) that
the child will not be affected

Genetic Testing

- Genetic Dx required for family planning
- Clinically available through several labs in US and worldwide
- PCR-based, 2-4 weeks
- Test cost \$290-700 (lab, self- insurance-institutional billing)
- Insurance coverage:
 - ▣ **CPT codes: 81401x1**
 - ▣ **ICD10 codes: G71.11**

Myotonic Dystrophy (DM)





2016 MDF ANNUAL CONFERENCE

September 15-17 2016, Washington DC



MYOTONIC
DYSTROPHY
FOUNDATION

Care and a Cure

FAMILY-BUILDING OPTIONS FOR MYOTONIC DYSTROPHY

Family-Building Options



Family-Building Options

IVF + PGD



Prenatal
Testing



Donor Eggs/
Sperm



Adoption

IVF + PGD

- **IVF: In Vitro Fertilization**

- Combine eggs & sperm in lab to create embryos


- **PGD: Preimplantation Genetic Diagnosis**

- Genetic testing of embryos created by IVF
- Only “unaffected” embryos (without DM) transferred to woman’s womb to start pregnancy

IVF + PGD

- Woman takes medications (oral and injections) to regulate cycle and stimulate ovaries to produce multiple eggs, monitored by frequent ultrasounds and blood tests
- Eggs retrieved (minor surgery), male partner provides semen sample
- Eggs fertilized by intracytoplasmic sperm injection (ICSI)
- Early embryos grow in lab for several days
- **PGD:** Embryo biopsy 3-6 days after fertilization, perform genetic testing on single cells (results may take several days or longer so often embryos will be frozen and transferred in a subsequent cycle)
- Transfer of one or more embryos to womb

IVF + PGD



IVF + PGD



IVF + PGD: Pros & Cons

ADVANTAGES

- Increases likelihood of birth of unaffected child without need for termination of an ongoing pregnancy
- Highly accurate

DISADVANTAGES

- You don't get to conceive the "fun" way!
- IVF not always successful, may need multiple cycles
- Costly, may not be covered by insurance

IVF + PGD: Financial Considerations

	Approximate Cost
Fresh IVF Cycle	\$12,400*
ICSI	~ \$1,500
Medications	~ \$3,000-5,000
PGD	~ \$5,000
TOTAL	~ \$20,000 - \$25,000

- Costs and insurance coverage varies widely
- Don't assume it's not covered! Schedule consultation with IVF/PGD clinic to find out actual costs, your specific insurance coverage, and financial options

**U.S. average [source: www.asrm.org]*

IVF + PGD: Financial Considerations

- Many resources available:
 - ▣ Refund programs through IVF clinics
 - ▣ Discounts for military/veterans
 - ▣ Financing and loans
 - ▣ Grants
 - ▣ Crowdfunding



ABOUT INFERTILITY

FAMILY BUILDING OPTIONS

Making Treatment Affordable

www.resolve.org

Prenatal Testing


- Get pregnant “naturally”
- Genetic testing during pregnancy
- Option to end pregnancy if baby has DM
- Two procedures
 - ▣ **Chorionic villus sampling (CVS)**: performed 11-13 weeks
 - ▣ **Amniocentesis**: performed at 15-20 weeks
- Highly accurate, small risk of miscarriage

Prenatal Testing

- Two procedures
 - **Chorionic villus sampling (CVS)**
Performed at 11-13 weeks (~3 months)
 - **Amniocentesis (Amnio)**
Performed at 15-20 weeks (~4-5 months)


Prenatal Testing: CVS

- Needle through abdomen or catheter through cervix to obtain chorionic villi (part of placenta)
- Risk of miscarriage = 1 / 200 (0.5%)



Prenatal Testing: Amnio

- Needle through abdomen to remove small amount of amniotic fluid that contains cells from baby
- Risk of miscarriage = 1 / 300 (0.3%) or less



Prenatal Testing: Pros & Cons

ADVANTAGES

- Highly accurate (>99%)
- Likely covered by insurance

DISADVANTAGES

- Cannot “fix” abnormal gene, option is to end pregnancy (abortion)
- Small risk of miscarriage

Donor Eggs/Sperm

- Use eggs or sperm from donor who does not have myotonic dystrophy
- Available from storage banks
- Donor sperm can be inseminated directly into the woman's womb or used in IVF procedures
- Donor eggs can be used in IVF procedures

Donor Eggs/Sperm: Pros & Cons

ADVANTAGES

- Guaranteed child without DM, no need for genetic testing of embryo or fetus
- Child is genetically related to one parent
- Woman can carry pregnancy

DISADVANTAGES

- Child is not genetically related to one parent
- May not be covered by insurance

Adoption

- Many different types of adoption
 - ▣ Domestic or international
 - ▣ Closed or open
 - ▣ Foster to adoption
- Financial resources and tax credits available
- <http://www.resolve.org/family-building-options/adoption/>

Adoption

□ <https://www.childwelfare.gov/topics/adoption/>



U.S. Department of Health & Human Services



Administration for Children & Families



Children's Bureau



**Child Welfare
Information Gateway**

PROTECTING CHILDREN ■ STRENGTHENING FAMILIES

How to Adopt

In this section you will find basic resources about who can adopt, things to consider before adoption, an explanation of the many adoption choices available (including domestic, intercountry, and open adoption), home study requirements, finding an agency, adoption by different types of families (including single; stepparent; transracial/transcultural; military; or lesbian, gay, bisexual, or transgender (LGBT) families), and assistance with adoption expenses.

- Who can adopt?
- Making the decision to adopt
- What are my choices in adoption?
- Who are the children waiting for families?
- Home study
- Finding an adoption agency
- Adoption by family type
- Adoption costs and sources of financial support

Adoption: Pros & Cons

ADVANTAGES

- Guaranteed child without DM, no need for genetic testing of embryo or fetus
- Provide home and family to child who needs one 😊

DISADVANTAGES

- Child is not genetically related to either parent, woman does not carry pregnancy

Family-Building Options

IVF + PGD



Prenatal
Testing




Donor Eggs/
Sperm



Adoption

Decision-Making



Decision-Making

- When deciding whether to take action to prevent passing on a genetic condition, individuals consider
 - ▣ Nature and severity of disease
 - ▣ Age of onset
 - ▣ Quality of life
 - ▣ Availability of treatment currently and future prospects
- Many of these aspects are subjective and/or uncertain
- Influenced by lived experience with the condition

Choosing among the options

- How important is it that the child be genetically related to you?
- How important is it that you or your partner carry a pregnancy?
- Would you be willing to terminate an affected pregnancy?
- What will your finances allow?

General advice

- “Try on” each option – spend time imagining how it would feel and what your life would look like if you go that route
- Different family members do not always agree – this is normal
- There is no absolute “right” or “wrong” choice
- If you are really struggling with a decision, seek out individual or couples counseling

Resources

- National Society of Genetic Counselors

- www.nsgc.org



- Resolve

- www.resolve.org

- Genetics Fact Sheets

- <http://www.genetics.edu.au/Publications-and-Resources/Genetics-Fact-Sheets>

Resources

MATERNAL MYOTONIC DYSTROPHY AND PREGNANCY



2016 MDF ANNUAL CONFERENCE

September 15-17 2016, Washington DC



MYOTONIC
DYSTROPHY
FOUNDATION

Care and a Cure

Karin J. Blakemore, M.D.
Director, Prenatal Genetics
Division of Maternal-Fetal Medicine
Johns Hopkins University School of Medicine

Myotonic Dystrophy

□ DM1

- Distal muscle weakness and wasting
- Facial muscle involvement
 - Ptosis
 - Tent-shaped mouth
- CTG trinucleotide repeat DM protein kinase gene (DMPK)

□ DM2

- Proximal muscle weakness of lower limbs
- Later onset and more favorable course
- CCTG tetranucleotide repeat Zinc finger 9 protein gene (CNBP)

- Phenotypes of DM1 and DM2 overlap somewhat

Myotonic Dystrophy Type I

DM1

- **Most common heritable neuromuscular disorder**
 - ▣ **1 in 8,000**
- **Progressive muscle weakness and wasting**
- **Myotonia**
- **Cataract Formation**
- **Endocrine abnormalities**
 - ▣ **Diabetes mellitus**
 - ▣ **Gonadal dysfunction in men**

Myotonic Dystrophy Type I

DM1

- **DM1 is caused by a triplet repeat expansion (CTG) in non-coding region of the “myotonin” gene, the DM protein kinase gene (DMPK) at 19q13.3**
- **Normal repeat size 5 – 34**
- **Affected individuals have 50 – thousands of repeats**
 - ▣ **Severity correlates with number of repeats**
- **Congenital form nearly always occurs to an affected mother (i.e. rarely to an affected father)**
 - ▣ **Premutation alleles 35-49 repeats in unaffected parent**

Myotonic Dystrophy Type I

DM1

3 Types:

- ▣ **Mild**

- ▣ **Classic**


- ▣ **Congenital**



Congenital DM1

Neonatal Characteristics

- **Floppy**
- **Facial diplegia and tent-shaped mouth**
- **Talipes**
- **Respiratory difficulties**
 - ▣ **Diaphragmatic hypoplasia**
 - ▣ **Improves with time**
- **20% Neonatal Mortality**
- **GI Dysmotility**
- **Cerebral ventriculomegaly rarely requiring V-P shunt**
- **Survivors have significant learning disability**



Classic DM1



Neurology / Volume 17 / February 1967

The effect of pregnancy on dystrophia myotonica

Anthony Hopkins, M.R.C.P., and Shirley Wray, M.R.C.P.

Maternal DM1 and Pregnancy

- **Muscle weakness and myotonia stay the same or worsen**
 - **Usually manifests in third trimester, if at all**
 - **Progesterone effect?**
 - **Improves in the puerperium / postpartum**
- **Regular moderate exercise encouraged**
 - **Prolonged inactivity worsens symptoms**

Maternal DM1 and Pregnancy

Caution (or avoidance) in use of Magnesium Sulfate

- ▣ **Anti-seizure prophylaxis for Preeclampsia**
- ▣ **Fetal “Neuroprotection” in Preterm Labor**
- ▣ **Tocolysis for Preterm Labor**

Maternal DM1

Anesthetic Considerations

- Impaired pulmonary ventilation may be aggravated by even small doses of respiratory depressants
- General anesthesia of particular risk
 - ▣ Exaggerated responses to paralytic agents
- Occasionally prolonged post-op intubation is required
- Diminished cough reflex increases risk for aspiration pneumonia
- Cardiac arrhythmias associated with DM1

DM1 and Cardiac Arrhythmias

- **Intraventricular Conduction Defects**
- **First-degree Heart Block**
- **Non-sustained Supraventricular Tachycardia**

and

Non-sustained Ventricular Tachycardia

} Both more common
in DM2

- ***Risk of sudden cardiac death.***
- **ECG and Holter monitoring are recommended.**

Acta Obstet Gynecol Scand 65:667–668, 1986

CASE REPORT

OBSTETRIC COMPLICATIONS AS THE FIRST SIGN OF MYOTONIC DYSTROPHY

Ditlev Fossen and Leif Gjerstad

From the Department of Obstetrics & Gynecology, Sarpsborg Sykehus, Sarpsborg, and the Department of Neurology, Rikshospitalet, The National Hospital, University of Oslo, Oslo, Norway

Maternal DM1 and Pregnancy

Problems can occur in all 3 stages of labor & postpartum

- ▣ **Attributable to generalized muscle weakness and *decreased myometrial contractility***
- ▣ **Increased risk for cesarean section and postpartum hemorrhage**
 - **Failure to progress**
 - **Failure to descend**
 - **Uterine atony**

Maternal DM1 and Pregnancy

Problems can occur in all 3 stages of labor & postpartum

- ▣ **Attributable to generalized muscle weakness and *decreased myometrial contractility***
- ▣ **Increased risk for cesarean section and postpartum hemorrhage**
 - **Failure to progress**
 - **Failure to descend**
 - **Uterine atony**

The affected congenital DM1 fetus *also* promotes maternal obstetrical complications.

Maternal DM1 and Pregnancy

Problems can occur in all 3 stages of labor & postpartum

- ▣ **Attributable to generalized muscle weakness and *decreased myometrial contractility***
- ▣ **Increased risk for cesarean section and postpartum hemorrhage**
 - **Failure to progress**
 - **Failure to descend**
 - **Uterine atony**

The affected congenital DM1 fetus *also* promotes maternal obstetrical complications.

Many pregnant women with DM1 are undiagnosed!

Lesson of the Week

Do you shake hands with mothers of floppy babies?

T H H G KOH

Congenital DM1

Neonatal Characteristics

- **Floppy**
- **Facial diplegia and tent-shaped mouth**
- **Talipes**
- **Respiratory difficulties**
 - ▣ **Diaphragmatic hypoplasia**
 - ▣ **Improves with time**
- **20% Neonatal Mortality**
- **GI Dysmotility**
- **Cerebral ventriculomegaly rarely requiring V-P shunt**
- **Survivors have significant learning disability**



***In utero* the fetus with Congenital DM1 presents in a very similar way as the neonate.**

Most women experience decreased fetal movement.


This and the other fetal manifestations are able to be visualized by prenatal ultrasound.

Fetal Effects of Congenital

DM1

Fetal hypotonia/myotonia leads to:

- ▣ **Decreased fetal movement**
 - **Facial diplegia and tent-shaped mouth**
 - **Talipes**
 - **Breech presentation**
- ▣ **Decreased fetal swallowing**
 - **POLYHYDRAMNIOS**









Mild Cerebral Ventriculomegaly

Fetal Effects of Congenital


DM1

Fetal hypotonia/myotonia leads to: **on Obstetrical Outcomes**


- ▣ **Decreased fetal movement**
 - Facial diplegia and tent-shaped mouth
 - Talipes
 - Breech presentation
 - **Increased cesarean section rate**
- ▣ **Decreased fetal swallowing**
 - **POLYHYDRAMNIOS**
 - **Preterm Premature Rupture of Membranes (PPROM)**
 - **Preterm labor**
 - **Preeclampsia**
 - **Uterine Atony**
 - **Postpartum Hemorrhage**

Affected Congenital DM1 Fetus

Fetal Muscle Tone




Affected Congenital DM1 Fetus



Affected Congenital DM1 Fetus

Fetal Muscle Tone



Affected Mother (Symptomatic)

Fatigue

Occasional respiratory compromise/ Prolonged post-op intubation

Poor Myometrial Contractility

1st Stage of Labor: Dysfunctional Labor


2nd Stage of Labor: Poor expulsive effort

3rd Stage of Labor: Atony

Cesarean section)

Postpartum Hemorrhage

**Operative delivery rate
(including**



Contraception in Women with DM1

- While progesterone is postulated to possibly aggravate DM1 symptoms in pregnancy, there is no literature to support avoiding progesterone in the smaller doses associated with contraceptive methods (e.g. oral contraceptives, progestin injection, and progestin-containing implants or IUDs).
- Non-hormonal IUDs can cause increased menstrual flow, which may be an undesirable side-effect in patients whose myometrial contractility may be diminished.

Contraception in Women with DM1

- **No form of contraception is contraindicated in DM1, and patient response to the method chosen will vary, as in the general population.**
- **Individual's DM1 disease progression with increasing age may influence family planning decision-making in terms of timing (consider not delaying child-bearing to be healthy for pregnancy).**
- **Postpartum Tubal Ligation under epidural may be preferable to interval tubal ligation under general anesthesia.**

Summary

Many women with Classic DM1 are relatively asymptomatic and are undiagnosed before conceiving a pregnancy.

Maternal DM1 can lead to obstetrical complications even if the fetus is not affected.

Congenital DM1 can *further* complicate her pregnancy, labor, delivery, and postpartum course.

Summary

Even recent cases series describe ~50% of maternal Classic DM1 only being diagnosed through an offspring affected with Congenital DM1

--During pregnancy, through the fetal presentation of polyhydramnios, decreased fetal movement, talipes, facial diplegia, and mild cerebral ventriculomegaly

--Or postpartum, by the neonatal presentation of hypotonia, respiratory insufficiency, facial diplegia, and talipes.

In light of the potentially life-threatening and avoidable obstetrical complications that may ensue, prenatal recognition of Congenital DM1 is highly important not only for the fetus, but also for the mother.

Summary

As devastating as it is, the diagnosis of Congenital DM1 in the baby can provide the key to appropriate planning and obstetrical management decisions which can be life-saving to the mother.

Lesson of the Week

Do you shake hands with mothers of floppy babies?

T H H G KOH

Do you shake hands with mothers with polyhydramnios, decreased fetal movement and sonographic signs of fetal hypotonia?

References

- Hopkins A, Wray S. The effect of pregnancy on dystrophica myotonica. *Neurology* 1967; 17:166-8.
- Hillard GD, Harris RE, Gilstrap LC, Shoumaker RD. Myotonic muscular dystrophy in pregnancy. *Southern Med J* 1977; 70:446-7.
- Webb D, Muir I, Faulkner J, Johnson G. Myotonia dystrophica: obstetric complications. *Am J Obstet Gynecol* 1978; 132:265-70.
- Cope J. Myotonic dystrophy and pregnancy. *Aust New Zeal J Obstet Gynaecol* 1981; 21:240-1.
- Koh TH. Do you shake hands with mothers of floppy babies? *Br Med J (Clin Res Ed)*. 1984 Aug 25;289(6443):485.
- Sun SF, Binder J, Streib E, Goodlin RC. Myotonic dystrophy: obstetric and neonatal complications. *South Med J*. 1985 Jul;78(7):823-6.

References (cont.)

- Aldridge LM. Anaesthetic problems in myotonic dystrophy. *Br J Anesth* 57 (1985) 1119.
- Nazir MA, Dillon WP, McPherson EW. Myotonic dystrophy in pregnancy. *J Reprod Med* 1984; 29:168-72.
- Jaffe R, Mock M, Abramowicz J, Ben-Aderet N. Myotonic dystrophy and pregnancy: a review. *Obstet Gynecol Survey* 1986; 41:272-8.
- Fossen D, Gjerstad L. Obstetric complications as the first sign of myotonic dystrophy. *Acta Obstet Gynecol Scand* 1986;65:667-8.
- Atlas I, Smolin A. Combined maternal and congenital myotonic dystrophy managed by a multidisciplinary team. *Eur J Obstet Gynecol Reprod Biol.* 1999 Dec;87(2):175-8.

References (cont.)

- Mashiach R, Rimon E, Achiron R. Tent-shaped mouth as a presenting symptom of congenital myotonic dystrophy. *Ultrasound Obstet Gynecol.* 2002 Sep;20(3):312-3.
- Rudnik-Schoneborn S, Zerres K. Outcome in pregnancies complicated by myotonic dystrophy: a study of 31 patients and review of the literature. *Eur J Obstet Gynecol Reprod Biol.* 2004; 114:44-53
- Zaki M, Boyd PA, Impey L, Roberts A, Chamberlain P. Congenital myotonic dystrophy: prenatal ultrasound findings and pregnancy outcome. *Ultrasound Obstet Gynecol.* 2007 Mar;29(3):284-8.
- Catanzarite V, Gambling D, Bird LM, Honold J, Perkins E. Respiratory compromise after MgSO₄ therapy for preterm labor in a woman with myotonic dystrophy: a case report. *J Reprod Med.* 2008 Mar;53(3):220-2.
- Faulkner C, Kingston H. Knowledge, views, and experience of 25 women with myotonic dystrophy. *J Med Genet.* 1998 Dec;35(12):1020-5.